Contineum Therapeutics (CTNM) Cash from Financing Activities (2023 - 2026)

Contineum Therapeutics' Cash from Financing Activities history runs 4 years deep, the most recent figure standing at $1.2 million for Q2 2026.

• In Q2 2026, Cash from Financing Activities rose 1218.68% year-over-year to $1.2 million; the TTM figure through Jun 2026 stood at $113.9 million (up 14692.08% YoY), while the FY2025 annual figure was $112.7 million, up 3.38% from the prior year.
• Cash from Financing Activities for Q2 2026 stood at $1.2 million, up from $129000.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $108.4 million in Q2 2024, with the low at -$617000.0 in Q1 2023.
• The 4-year median for Cash from Financing Activities is $385500.0 (2024), against an average of $19.9 million.
• Peak annual rise in Cash from Financing Activities reached 146861.54% in 2025, while the deepest fall reached 99.92% in 2025.
• Contineum Therapeutics' Cash from Financing Activities stood at -$321000.0 in 2023, then jumped by 300.0% to $642000.0 in 2024, then jumped by 14458.41% to $93.5 million in 2025, then plunged by 98.72% to $1.2 million in 2026.
• Business Quant data shows CTNM's Cash from Financing Activities at $1.2 million in Q2 2026, $129000.0 in Q1 2026, and $93.5 million in Q4 2025.